Released Nov 14, 2024, after the close
10-Q filed Nov 14, 2024, 45 days after period end · 0000950170-24-127016
Q3 2024 · 10-Q
Revenue$65.00K$65.00K −70.2% vs Q3 2023−43.0% vs Q2 2024
Net Income-$17.15M-$17.15M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.32-$0.32 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$18,593,000N/M
Operating Cash Flowderived$12,763,000−19.8%
Margins · derived
Operating margin-28604.6%−27717.5 pt vs Q3 2023
Net margin-26380.0%−24912.1 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $65.00K | $218.00K | $1.08M | $708.00K |
| Net Income | -$17.15M | -$3.20M | -$11.70M | -$22.50M |
| EPS Diluted | -$0.32 | -$0.06 | -$0.33 | -$0.70 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR